To ask the Secretary of State for Environment, Food and Rural Affairs, whether his Department has made an assessment of the potential impact of neonicotinoids in spot pet treatments on natural habitats.

To ask the Secretary of State for Environment, Food and Rural Affairs, what assessment he has made of the potential impact of the use of neonicotinoids in spot pet treatments on the environment.

Parasiticides play an important role in the protecting of animal health from fleas, ticks, and vector-borne diseases, and in protecting human health from zoonotic transfer of disease. Therefore, their regulation requires a careful balance between effective parasite control for animal health and welfare and human health whilst minimising potential risks to the environment.

To address environmental safety, every veterinary pharmaceutical undergoes an environmental exposure assessment, with products for companion animals usually ending in a phase 1 assessment. If exposure is deemed high, a more detailed Phase II risk assessment is conducted, evaluating potential environmental impact based on expected exposure and toxicity. The findings from these assessments are considered as part of the final benefit/risk assessment during the approval process. There are also warnings that accompany products advising on use and to mitigate against dogs entering water courses directly after treatment. Environmental assessments are conducted in accordance with international guidelines and data standards.

The Veterinary Medicines Directorate (VMD) is conducting a number of research activities to provide further evidence on environmental impacts and causes. Furthermore, the VMD supports a review of the international environmental risk assessment guidelines for companion animal parasiticides, which has been proposed and is currently under consideration by the body for International Cooperation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH).